ARTA
TRIB

A.R.T. Advisors’s Trinity Biotech TRIB Stock Holding History

A.R.T. Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-153
Closed -$137K – 1720
2017
Q1 		$137K Buy
153
+64
+72% +$60K 0.01% 1233
2016
Q4 		$92K Buy
+89
New +$92K 0.01% 1158
2016
Q1 		– Sell
-232
Closed -$408K – 1647
2015
Q4 		$408K Buy
+232
New +$411K 0.02% 946
2015
Q1 		– Sell
-109
Closed -$287K – 1692
2014
Q4 		$287K Buy
109
+36
+49% +$93.1K 0.01% 1114
2014
Q3 		$200K Buy
+73
New +$237K 0.01% 1098

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

A.R.T. Advisors's TRIB Position: Q2 2017 in Review

A.R.T. Advisors sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 153 shares — an estimated $137K sold.

A.R.T. Advisors first reported a position in TRIB in Q3 2014 and held it in 5 quarters. The position peaked at $408K in Q4 2015. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • A.R.T. Advisors reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 153 Trinity Biotech shares in Q2 2017, an estimated $137K.
  • A.R.T. Advisors first reported a position in Trinity Biotech in Q3 2014 and held it in 5 quarters.
  • A.R.T. Advisors's Trinity Biotech position peaked at $408K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.